GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Quick Ratio

Dianthus Therapeutics (Dianthus Therapeutics) Quick Ratio : 42.52 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Dianthus Therapeutics's quick ratio for the quarter that ended in Mar. 2024 was 42.52.

Dianthus Therapeutics has a quick ratio of 42.52. It generally indicates good short-term financial strength.

The historical rank and industry rank for Dianthus Therapeutics's Quick Ratio or its related term are showing as below:

DNTH' s Quick Ratio Range Over the Past 10 Years
Min: 1.75   Med: 14.64   Max: 42.52
Current: 42.52

During the past 3 years, Dianthus Therapeutics's highest Quick Ratio was 42.52. The lowest was 1.75. And the median was 14.64.

DNTH's Quick Ratio is ranked better than
97.94% of 1555 companies
in the Biotechnology industry
Industry Median: 3.53 vs DNTH: 42.52

Dianthus Therapeutics Quick Ratio Historical Data

The historical data trend for Dianthus Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Quick Ratio Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Quick Ratio
1.75 9.97 18.42

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial 9.97 - 14.64 18.42 42.52

Competitive Comparison of Dianthus Therapeutics's Quick Ratio

For the Biotechnology subindustry, Dianthus Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dianthus Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Quick Ratio falls into.



Dianthus Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Dianthus Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(177.451-0)/9.631
=18.42

Dianthus Therapeutics's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(380.926-0)/8.959
=42.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dianthus Therapeutics  (NAS:DNTH) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Dianthus Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines